US5521222A
(en)
*
|
1989-09-28 |
1996-05-28 |
Alcon Laboratories, Inc. |
Topical ophthalmic pharmaceutical vehicles
|
US5461081A
(en)
*
|
1989-09-28 |
1995-10-24 |
Alcon Laboratories, Inc. |
Topical ophthalmic pharmaceutical vehicles
|
US5932572A
(en)
*
|
1992-02-21 |
1999-08-03 |
Alcon Laboratories, Inc. |
Topical anti-glaucoma compositions
|
ES2118941T3
(es)
*
|
1992-02-21 |
1998-10-01 |
Alcon Lab Inc |
Composiciones antiglaucoma topicas que comprenden inhibidores de anhidrasa carbonica y bloqueantes beta.
|
CA2141879A1
(en)
*
|
1992-09-17 |
1994-03-31 |
Thomas Robert Dean |
Topical carbonic anhydrase inhibitor composition
|
SE9301877D0
(sv)
*
|
1993-06-02 |
1993-06-02 |
Kabi Pharmacia Ab |
In situ gel for therapeutic use
|
EP0708646A1
(de)
*
|
1994-05-06 |
1996-05-01 |
Alcon Laboratories, Inc. |
Verwendung von vitamin e tocopherolderivaten in ophthalmischen präparaten
|
US6172054B1
(en)
|
1995-06-15 |
2001-01-09 |
Alcon Laboratories, Inc. |
Combination therapy for lowering and controlling intraocular pressure
|
US5696166A
(en)
*
|
1995-10-31 |
1997-12-09 |
Yanni; John M. |
Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
|
US6441047B2
(en)
|
1995-11-17 |
2002-08-27 |
Alcon Manufacturing Ltd.. |
Combination therapy for treating glaucoma
|
EP1057486A1
(de)
*
|
1995-11-17 |
2000-12-06 |
Alcon Laboratories, Inc. |
Verwendung einer Medikamentenkombination zur Behandlung von Glaukom
|
FR2754712B1
(fr)
|
1996-10-17 |
1999-09-03 |
Merck Sharp Dohme Chibret Lab |
Compositions ophtalmiques
|
CH690814A5
(it)
*
|
1996-11-04 |
2001-01-31 |
Applied Pharma Res |
Composizioni per uso topico contenenti polisaccaridi solfati.
|
ZA989513B
(en)
|
1997-10-21 |
1999-04-21 |
Alcon Lab Inc |
Compositions containing histamine H2 agonists and methods of use in treating dry eye
|
US6174524B1
(en)
|
1999-03-26 |
2001-01-16 |
Alcon Laboratories, Inc. |
Gelling ophthalmic compositions containing xanthan gum
|
US6261547B1
(en)
|
1998-04-07 |
2001-07-17 |
Alcon Manufacturing, Ltd. |
Gelling ophthalmic compositions containing xanthan gum
|
AU2183900A
(en)
|
1998-12-24 |
2000-07-31 |
Alcon Laboratories, Inc. |
Ep4 receptor agonists for treatment of dry eye
|
AU2183800A
(en)
|
1998-12-24 |
2000-07-31 |
Alcon Laboratories, Inc. |
Prostaglandin e agonists for treatment of dry eye
|
WO2000043395A1
(en)
|
1999-01-25 |
2000-07-27 |
National Jewish Medical And Research Center |
Substituted porphyrins
|
MXPA02004349A
(es)
|
1999-11-01 |
2003-09-22 |
Alcon Inc |
Composiciones farmaceuticas que contienen un farmaco antibiotico de fluoroquinolona y goma de xantano.
|
MXPA02004703A
(es)
|
1999-11-09 |
2004-09-10 |
Alcon Inc |
Composiciones que contienen derivados de acido hidroxieicostetraenoico y metodos de uso para tratar trastornos de resequedad en los ojos.
|
AU1226001A
(en)
|
1999-11-09 |
2001-06-06 |
Alcon Universal Limited |
Phospholipids of hydroxyeicosatetraenoic acid-like derivatives
|
BR0015423A
(pt)
|
1999-11-09 |
2002-07-09 |
Alcon Inc |
Análogos de ácido 15-hidroxieicosatetraenóico interrompidos por heteroátomo e métodos de uso
|
WO2001034548A2
(en)
|
1999-11-09 |
2001-05-17 |
Alcon Universal Ltd. |
3-heteroatom substituted and two carbon homologs of 15-hete and methods of use
|
DE60020591T2
(de)
|
1999-11-09 |
2005-11-10 |
Alcon Inc. |
Benzenoidderivate von 15-hydroxyeicosatetraesäure und verfahren zur verwendung zur behandlung des trockenen auges
|
US6255343B1
(en)
|
1999-11-09 |
2001-07-03 |
Alcon Universal Ltd. |
2,2-difluoro 15-hydroxyeicosatetraenoic acid analogs and methods of use
|
US6552084B2
(en)
|
1999-11-09 |
2003-04-22 |
Alcon Universal Ltd. |
Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
|
WO2001034550A2
(en)
|
1999-11-09 |
2001-05-17 |
Alcon Universal Ltd. |
15-hydroxyeicosatetraenoic acid analogs with enhanced metabolic stability and methods of their use in treating dry eye disorders
|
US6353012B1
(en)
|
1999-11-09 |
2002-03-05 |
Alcon Universal Ltd. |
15-Hydroxyeicosatetraenoic acid-related compounds and methods of use
|
US6803385B2
(en)
|
1999-11-09 |
2004-10-12 |
Alcon, Inc. |
Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
|
TR200201244T2
(tr)
|
1999-11-09 |
2002-08-21 |
Alcon, Inc. |
Göz kurumasının iyileştirilmesi için Lipoksin A4 ve analogları
|
WO2001034549A1
(en)
|
1999-11-09 |
2001-05-17 |
Alcon Universal Ltd. |
Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disorders
|
TR200201251T2
(tr)
|
1999-11-09 |
2002-11-21 |
Alcon, Inc. |
Omega zinciri tadil edilmiş 15-hidroksieikosatetraenoik asit türevleri ve bunların göz kurumasının iyileştirilmesi için kullanım yöntemleri
|
US6458854B2
(en)
|
1999-11-09 |
2002-10-01 |
Alcon Universal Ltd. |
Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use
|
WO2001046134A1
(en)
|
1999-12-22 |
2001-06-28 |
Alcon Universal Ltd. |
6-KETO PROSTAGLANDIN F1α AND ANALOGS FOR TREATING DRY EYE
|
EP1305033B1
(de)
|
2000-07-28 |
2004-10-20 |
Alcon, Inc |
Pharmazeutische zusammensetzungen enthaltend tobramycin und xanthangummi
|
AR031135A1
(es)
|
2000-10-10 |
2003-09-10 |
Upjohn Co |
Composiciones de antibiotico topico para el tratamiento de infecciones oculares
|
WO2002040056A2
(en)
|
2000-11-06 |
2002-05-23 |
Alcon, Inc |
Carrageenan viscoelastics for ocular surgery
|
US20030060447A1
(en)
*
|
2002-04-24 |
2003-03-27 |
Mutlu Karakelle |
Non-aspirating transitional viscoelastics for use in surgery
|
BR0209883A
(pt)
|
2001-05-21 |
2004-06-08 |
Alcon Inc |
Uso de inibidores da proteasoma para o tratamento de distúrbios do olho seco
|
BR0209965A
(pt)
|
2001-05-21 |
2004-04-06 |
Alcon Inc |
Uso de inibidores de nf-kappab para tratar distúrbios do olho seco
|
US6872382B1
(en)
|
2001-05-21 |
2005-03-29 |
Alcon, Inc. |
Use of selective PDE IV inhibitors to treat dry eye disorders
|
BR0209882A
(pt)
*
|
2001-05-21 |
2004-06-08 |
Alcon Inc |
Método para o tratamento de distúrbios de olho seco
|
US7112588B2
(en)
*
|
2001-05-21 |
2006-09-26 |
Alcon, Inc. |
Use of proteasome inhibitors to treat dry eye disorders
|
AU2002312194B8
(en)
*
|
2001-06-01 |
2008-05-15 |
Aeolus Sciences, Inc. |
Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
|
US6645994B1
(en)
|
2001-06-01 |
2003-11-11 |
Alcon, Inc. |
Method of treating dry eye disorders
|
US6750250B1
(en)
|
2001-07-12 |
2004-06-15 |
Alcon, Inc. |
11,12-oxidoarachidonic acid derivatives and methods of their use in treating dry eye disorders
|
US20040214754A1
(en)
*
|
2001-10-03 |
2004-10-28 |
Ellis Edward J. |
Ophthalmic preparation containing glycomacropeptide
|
US20040220089A1
(en)
*
|
2001-10-03 |
2004-11-04 |
Ellis Edward J. |
Ophthalmic preparation containing glycoprotein
|
US20060234944A1
(en)
*
|
2001-10-23 |
2006-10-19 |
Oklahoma Medical Reseach Foundation |
Beta-secretase inhibitors and methods of use
|
JP4547152B2
(ja)
*
|
2001-10-23 |
2010-09-22 |
オクラホマ メディカル リサーチ ファウンデーション |
β−セクレターゼ阻害剤および使用方法
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
AR038576A1
(es)
*
|
2002-02-22 |
2005-01-19 |
Pharmacia Corp |
Formulaciones de drogas antibioticas oftalmicas que contienen un compuesto de ciclodextrina y cloruro de cetil piridinio
|
AU2003213210A1
(en)
*
|
2002-02-22 |
2003-09-09 |
Pharmacia Corporation |
Ophthalmic formulation with gum system
|
SI1534286T1
(sl)
|
2002-07-29 |
2010-04-30 |
Rigel Pharmaceuticals Inc |
Postopki za zdravljenje ali prepreŽŤevanje avtoimunskih bolezni z 2,4-pirimidindiaminskimi spojinami
|
US8580851B2
(en)
|
2002-08-21 |
2013-11-12 |
Sucampo Ag |
Ophthalmic solution
|
AU2003303623A1
(en)
*
|
2002-12-20 |
2004-07-29 |
Alcon, Inc. |
Treatment of dry eye by restoring 15-lipoxygenase activity to ocular surface cells
|
JP4741491B2
(ja)
|
2003-08-07 |
2011-08-03 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
抗増殖剤としての2,4−ピリミジンジアミン化合物および使用
|
CA2536281C
(en)
*
|
2003-08-21 |
2012-05-15 |
Sucampo Ag |
Ophthalmic composition comprising a 15-keto-prostaglandin compound
|
AU2005286774A1
(en)
*
|
2004-09-17 |
2006-03-30 |
Comentis, Inc |
Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof
|
EP1797052A1
(de)
*
|
2004-09-17 |
2007-06-20 |
Comentis, Inc. |
Bizyklische verbindungen zur verhinderung der aktivität von beta-sekretase und verwendungsverfahren dafür
|
US9512125B2
(en)
*
|
2004-11-19 |
2016-12-06 |
The Regents Of The University Of California |
Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
|
CA2604291A1
(en)
*
|
2005-04-08 |
2006-10-19 |
Comentis, Inc. |
Compounds which inhibit beta-secretase activity and methods of use thereof
|
US8962643B2
(en)
|
2006-02-24 |
2015-02-24 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the JAK pathway
|
TW200808375A
(en)
|
2006-05-12 |
2008-02-16 |
Otsuka Pharma Co Ltd |
Hydrogel suspension and manufacturing process thereof
|
CN101541783B
(zh)
|
2006-06-30 |
2014-10-01 |
苏尼西斯制药有限公司 |
吡啶酮基pdk1抑制剂
|
ES2380551T3
(es)
|
2006-11-21 |
2012-05-16 |
Rigel Pharmaceuticals, Inc. |
Sales de profármaco de compuestos de 2,4-pirimidindiamina y sus usos
|
KR20080076667A
(ko)
*
|
2007-02-15 |
2008-08-20 |
주식회사 중외제약 |
요변성 약학 조성물
|
DK2170283T3
(en)
|
2007-06-22 |
2019-04-15 |
Univ Texas |
CREATION OF STABLE SUBMICRON Peptide OR PROTEIN PARTICLES BY THIN FILM FREEZING
|
CA2697166A1
(en)
*
|
2007-07-26 |
2009-01-29 |
Comentis, Inc. |
Isophthalamide derivatives inhibiting betasecretase activity
|
KR20100059919A
(ko)
*
|
2007-09-24 |
2010-06-04 |
코멘티스, 인코포레이티드 |
치료를 위한 베타-세크레타제 억제제로서 (3-히드록시-4-아미노-부탄-2일)-3-(2-티아졸-2-일-피롤리딘-1-카르보닐) 벤즈아미드 유도체 및 관련 화합물
|
AU2008350907A1
(en)
|
2007-12-11 |
2009-08-27 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
|
KR20100133980A
(ko)
*
|
2008-03-07 |
2010-12-22 |
썬 파마 어드밴스트 리서치 컴패니 리미티드 |
안약 조성물
|
RU2506083C2
(ru)
|
2008-05-23 |
2014-02-10 |
Нэшнл Джуиш Хелт |
Способ лечения поражений, ассоциированных с воздействием алкилирующих веществ
|
US20110224223A1
(en)
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
US8618096B2
(en)
*
|
2008-07-21 |
2013-12-31 |
The Regents Of The University Of California |
Prodrug compositions and methods for using the same in treating cancer and malaria
|
WO2010031056A2
(en)
|
2008-09-15 |
2010-03-18 |
The Regents Of The University Of California |
Methods and compositions for modulating ire1, src, and abl activity
|
EP2382210B1
(de)
|
2008-12-30 |
2017-03-01 |
Rigel Pharmaceuticals, Inc. |
Pyrimidindiamine als kinaseinhibitoren
|
MX2011007750A
(es)
|
2009-01-23 |
2011-09-29 |
Rigel Pharmaceuticals Inc |
Composiciones y metodos para inhibicion de la ruta jak.
|
WO2010091198A1
(en)
|
2009-02-06 |
2010-08-12 |
University Of Southern California |
Therapeutic compositions comprising monoterpenes
|
JP2012516187A
(ja)
*
|
2009-02-20 |
2012-07-19 |
マイクロ ラブズ リミテッド |
貯蔵安定性プロスタグランジン製品
|
AU2010281404A1
(en)
|
2009-07-28 |
2012-02-09 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the JAK pathway
|
AU2010284255B2
(en)
|
2009-08-17 |
2016-11-17 |
Memorial Sloan-Kettering Cancer Center |
Heat shock protein binding compounds, compositions, and methods for making and using same
|
WO2011029046A1
(en)
|
2009-09-04 |
2011-03-10 |
Biogen Idec Ma Inc. |
Bruton's tyrosine kinase inhibitors
|
EP2485589A4
(de)
|
2009-09-04 |
2013-02-06 |
Biogen Idec Inc |
Heteroaryl-btk-hemmer
|
EP3070077B1
(de)
|
2009-10-06 |
2018-11-28 |
Millennium Pharmaceuticals, Inc. |
Als pdk1-inhibitoren nützliche heterocyclische verbindungen
|
US8980899B2
(en)
|
2009-10-16 |
2015-03-17 |
The Regents Of The University Of California |
Methods of inhibiting Ire1
|
EP2853262B1
(de)
|
2009-10-26 |
2016-11-30 |
Sephoris Pharmaceuticals, LLC |
Behandlung von Sonnenbrand mit Schmerzmitteln und Antihistaminen
|
CA2781056A1
(en)
|
2009-11-16 |
2011-05-19 |
Rebecca Maglathlin |
Kinase inhibitors
|
KR101849680B1
(ko)
|
2009-12-10 |
2018-04-17 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
아밀로이드 결합제
|
WO2011109635A1
(en)
|
2010-03-03 |
2011-09-09 |
Neonc Technologies Inc. |
Pharmaceutical compositions comprising monoterpenes
|
NZ718622A
(en)
|
2010-03-30 |
2018-03-23 |
Verseon Corp |
Multisubstituted aromatic compounds as inhibitors of thrombin
|
CA2837400C
(en)
|
2010-04-24 |
2017-12-12 |
Viamet Pharmaceuticals, Inc. |
5-(optionally substituted phenyl) pyridin-2-yl compounds as metalloenzyme inhibitors
|
PT2598500T
(pt)
|
2010-07-28 |
2021-07-22 |
Rigel Pharmaceuticals Inc |
Composições e métodos para a inibição da via jak
|
US20160038600A1
(en)
|
2012-08-03 |
2016-02-11 |
Neonc Technologies Inc. |
Pharmaceutical compositions comprising poh derivatives
|
CN110464718A
(zh)
|
2010-08-27 |
2019-11-19 |
尼昂克技术公司 |
包含poh衍生物的药物组合物
|
EP2632903A4
(de)
|
2010-10-28 |
2014-11-26 |
Viamet Pharmaceuticals Inc |
Metalloenzymhemmerverbindungen
|
EP2632898A4
(de)
|
2010-10-29 |
2014-04-02 |
Biogen Idec Inc |
Heterozyklische tyrosinkinase-hemmer
|
JP5828343B2
(ja)
|
2010-11-13 |
2015-12-02 |
イノクリン ファーマシューティカルズ,インコーポレイテッド |
金属酵素阻害化合物
|
CN103328452A
(zh)
|
2010-12-13 |
2013-09-25 |
威尔金制药有限公司 |
金属酶抑制剂化合物
|
DK2651864T3
(en)
|
2010-12-17 |
2016-09-05 |
Neonc Tech Inc |
Methods and devices for use of isoperillylalkohol
|
AU2012217922B2
(en)
|
2011-02-14 |
2017-05-04 |
Allergan, Inc. |
Ester derivatives of bimatoprost compositions and methods
|
CA2828360A1
(en)
|
2011-02-25 |
2012-08-30 |
The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services |
Chrysophaentin analogs that inhibit ftsz protein
|
CN103608028A
(zh)
|
2011-04-28 |
2014-02-26 |
南加利福尼亚大学 |
人类髓源抑制性细胞癌症标记
|
CN103717602B
(zh)
|
2011-05-17 |
2016-11-09 |
加利福尼亚大学董事会 |
激酶抑制剂
|
PL2710005T3
(pl)
|
2011-05-17 |
2017-07-31 |
Principia Biopharma Inc. |
Inhibitory kinazy tyrozynowej
|
US9376438B2
(en)
|
2011-05-17 |
2016-06-28 |
Principia Biopharma, Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
WO2012162547A2
(en)
|
2011-05-25 |
2012-11-29 |
Amylin Pharmaceuticals, Inc. |
Long duration dual hormone conjugates
|
EA024385B1
(ru)
|
2011-06-19 |
2016-09-30 |
Ваймет Фармасьютикалс, Инк. |
Соединения, ингибирующие металлоферменты
|
CN105884743B
(zh)
|
2011-06-19 |
2019-08-06 |
威尔金制药(Nc)有限公司 |
金属酶抑制剂化合物
|
KR101964195B1
(ko)
|
2011-06-23 |
2019-04-01 |
비아멧 파마슈티컬즈(엔씨), 인코포레이티드 |
금속효소 억제제 화합물
|
AU2012279154A1
(en)
|
2011-07-01 |
2014-02-20 |
The Regents Of The University Of California |
Herpes virus vaccine and methods of use
|
EP2751112B1
(de)
|
2011-09-02 |
2019-10-09 |
The Regents of The University of California |
Substituierte pyrazolo[3,4-d]pyrimidine und ihre verwendung
|
WO2013063492A1
(en)
|
2011-10-28 |
2013-05-02 |
Board Of Regents, The University Of Texas System |
Novel compositions and methods for treating cancer
|
PT2788343T
(pt)
|
2011-12-11 |
2018-06-01 |
Viamet Pharmaceuticals Nc Inc |
Compostos inibidores de metaloenzimas
|
IN2014DN06792A
(de)
|
2012-01-20 |
2015-05-22 |
Viamet Pharmaceuticals Inc |
|
JP6231548B2
(ja)
|
2012-03-23 |
2017-11-15 |
マテオン セラピューティクス, インコーポレイテッド |
カテプシンの阻害のための組成物および方法
|
CN104379563B
(zh)
|
2012-04-10 |
2018-12-21 |
加利福尼亚大学董事会 |
用于治疗癌症的组合物和方法
|
WO2013173506A2
(en)
|
2012-05-16 |
2013-11-21 |
Rigel Pharmaceuticals, Inc. |
Method of treating muscular degradation
|
EP2858500A4
(de)
|
2012-06-08 |
2016-04-06 |
Biogen Ma Inc |
Hemmer der bruton-tyrosinkinase
|
AR091273A1
(es)
|
2012-06-08 |
2015-01-21 |
Biogen Idec Inc |
Inhibidores de pirimidinil tirosina quinasa
|
CA2913736A1
(en)
|
2012-06-11 |
2013-12-19 |
The Regents Of The University Of California |
Compounds and methods of treating cancer
|
US9090595B2
(en)
|
2012-08-27 |
2015-07-28 |
Allergan, Inc. |
Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
|
WO2014035827A1
(en)
|
2012-08-27 |
2014-03-06 |
Allergan, Inc. |
Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
|
RS58956B1
(sr)
|
2012-09-10 |
2019-08-30 |
Principia Biopharma Inc |
Jedinjenja pirazolopirimidina kao inhibitori kinaze
|
JP2015532287A
(ja)
|
2012-09-26 |
2015-11-09 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
Ire1の調節
|
JP6465803B2
(ja)
|
2012-10-22 |
2019-02-06 |
シティ・オブ・ホープCity of Hope |
Etp誘導体
|
US9364462B2
(en)
|
2012-10-30 |
2016-06-14 |
The Regents Of The University Of California |
Alpha-1-adrenergic receptor agonist therapy
|
EP2953950B1
(de)
|
2013-02-11 |
2021-01-13 |
The Regents of The University of California |
Zusammensetzungen und verfahren zur behandlung neurodegenerativer erkrankungen
|
EP2968296B1
(de)
|
2013-03-12 |
2020-09-02 |
The Regents of the University of California |
Gammasekretasemodulatoren
|
WO2014143591A1
(en)
|
2013-03-12 |
2014-09-18 |
Allergan, Inc. |
Inhibition of neovascularization by simultaneous inhibition of prostanoid ip and ep4 receptors
|
WO2014143592A1
(en)
|
2013-03-12 |
2014-09-18 |
Allergan, Inc. |
Inhibition of neovascularization by inhibition of prostanoid ip receptors
|
JP2016519662A
(ja)
|
2013-03-14 |
2016-07-07 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
K2pチャネルの調節
|
CA3123075C
(en)
|
2013-03-14 |
2023-09-19 |
The Regents Of The University Of California |
Thiosaccharide mucolytic agents
|
KR102275112B1
(ko)
|
2013-03-14 |
2021-07-08 |
시티 오브 호프 |
5-브로모-인디루빈
|
BR112015023705A8
(pt)
|
2013-03-15 |
2020-03-17 |
Univ California |
compostos, composições farmacêuticas, usos de um composto, e método para síntese do composto da fórmula (ia)
|
UY35464A
(es)
|
2013-03-15 |
2014-10-31 |
Araxes Pharma Llc |
Inhibidores covalentes de kras g12c.
|
EP2968297B1
(de)
|
2013-03-15 |
2018-09-26 |
Verseon Corporation |
Multisubstituierte aromatische verbindungen als serinproteaseinhibitoren
|
SG10201707486XA
(en)
|
2013-03-15 |
2017-10-30 |
Verseon Corp |
Halogenopyrazoles as inhibitors of thrombin
|
KR20150129735A
(ko)
|
2013-03-15 |
2015-11-20 |
알러간, 인코포레이티드 |
렙틴 생성의 향상을 위한 비마토프로스트
|
JP6806562B2
(ja)
|
2013-03-15 |
2021-01-06 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
eIF2α経路の調節因子
|
WO2014146111A2
(en)
|
2013-03-15 |
2014-09-18 |
The Regents Of The University Of California |
Analgesic compounds and methods of use
|
US8957080B2
(en)
|
2013-04-09 |
2015-02-17 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
WO2014190207A1
(en)
|
2013-05-22 |
2014-11-27 |
The Regents Of The University Of California |
Aurora kinase inhibitors
|
US9795691B2
(en)
|
2013-06-24 |
2017-10-24 |
City Of Hope |
Chemically-linked nanoparticles
|
AU2014290202B2
(en)
|
2013-07-15 |
2018-11-15 |
Board Of Regents, The University Of Texas System |
Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain
|
WO2015026849A1
(en)
|
2013-08-19 |
2015-02-26 |
The Regents Of The University Of California |
Compounds and methods for treating an epileptic disorder
|
JP2016530273A
(ja)
|
2013-08-20 |
2016-09-29 |
シティ・オブ・ホープCity of Hope |
癌を治療するためのhdac8阻害剤
|
WO2015031799A1
(en)
|
2013-08-30 |
2015-03-05 |
The Regents Of The University Of California, A California Corporation |
Scintillator nanocrystal-containing compositions and methods for their use
|
JO3805B1
(ar)
|
2013-10-10 |
2021-01-31 |
Araxes Pharma Llc |
مثبطات كراس جي12سي
|
KR102413253B1
(ko)
|
2013-12-11 |
2022-06-27 |
바이오젠 엠에이 인코포레이티드 |
종양, 신경 및 면역에서 인간 질환을 치료하는데 유용한 바이아릴 화합물
|
EP3080122B1
(de)
|
2013-12-11 |
2018-10-31 |
Biogen MA Inc. |
Zur behandlung von erkrankungen des menschen in der onkologie, neurologie und immunologie geeignete biarylverbindungen
|
MX2016008418A
(es)
|
2013-12-23 |
2017-01-11 |
Memorial Sloan Kettering Cancer Center |
Metodos y reactivos para el radiomarcaje.
|
PT2898888T
(pt)
*
|
2014-01-22 |
2019-07-16 |
Visufarma B V |
Composição que compreende iota-carragenina contra conjuntivite viral
|
WO2015116856A2
(en)
|
2014-01-29 |
2015-08-06 |
City Of Hope |
Farnesoid x receptor antagonists
|
CA2939219C
(en)
|
2014-02-11 |
2023-02-28 |
Mitokinin Llc |
Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
|
US10287312B2
(en)
|
2014-02-14 |
2019-05-14 |
The Regents Of The University Of California |
Cyclic peroxides as prodrugs for selective delivery of agents
|
WO2015175075A1
(en)
|
2014-02-20 |
2015-11-19 |
Allergan, Inc. |
Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
|
ES2841248T3
(es)
|
2014-02-21 |
2021-07-07 |
Principia Biopharma Inc |
Sales y forma sólida de un inhibidor de BTK
|
US20150259288A1
(en)
|
2014-03-14 |
2015-09-17 |
City Of Hope |
5-bromo-indirubins
|
EP3128842B1
(de)
|
2014-03-26 |
2023-07-26 |
City of Hope |
Behandlung von brca1-defektem krebs oder -resistentem krebs
|
ES2908240T3
(es)
|
2014-04-07 |
2022-04-28 |
Univ California |
Inhibidores de la enzima amida hidrolasa de ácidos grasos (FAAH) con biodisponibilidad oral mejorada y su uso como medicamentos
|
EA201692155A1
(ru)
|
2014-05-13 |
2017-04-28 |
Мемориал Слоун-Кеттеринг Кэнсэ Сентр |
МОДУЛЯТОРЫ Hsp70 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
|
WO2015183794A1
(en)
|
2014-05-27 |
2015-12-03 |
City Of Hope |
Tgr5 agonist complexes for treating diabetes and cancer
|
US10414814B2
(en)
|
2014-07-03 |
2019-09-17 |
City Of Hope |
Tumor-selective CTLA-4 antagonists
|
WO2016018917A2
(en)
|
2014-07-28 |
2016-02-04 |
The Regents Of The University Of Califoria |
Compositions and methods of making polymerized nucleic acids
|
WO2016023036A1
(en)
|
2014-08-08 |
2016-02-11 |
The Regents Of The University Of California |
High density peptide polymers
|
CN113620978A
(zh)
|
2014-09-11 |
2021-11-09 |
加利福尼亚大学董事会 |
mTORC1抑制剂
|
PL3194411T3
(pl)
|
2014-09-15 |
2022-06-20 |
The Regents Of The University Of California |
Analogi nukleotydów
|
JP2017528486A
(ja)
|
2014-09-17 |
2017-09-28 |
ヴァーセオン コーポレイション |
セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
US10011600B2
(en)
|
2014-09-25 |
2018-07-03 |
Araxes Pharma Llc |
Methods and compositions for inhibition of Ras
|
WO2016049524A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
AU2015327817B2
(en)
|
2014-10-02 |
2020-04-23 |
Allergan, Inc. |
Ester prodrugs of gamma-lactams and their use
|
PT3233103T
(pt)
|
2014-12-18 |
2021-01-18 |
Principia Biopharma Inc |
Tratamento de pênfigo
|
US10689423B2
(en)
|
2015-01-13 |
2020-06-23 |
City Of Hope |
CTLA4-binding protein peptide-linker masks
|
AU2016206475B2
(en)
|
2015-01-16 |
2021-11-04 |
City Of Hope |
Cell penetrating antibodies
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
CN107613768B
(zh)
|
2015-02-12 |
2020-10-20 |
NeOnc技术股份有限公司 |
包含紫苏醇衍生物的药物组合物
|
CA2977135C
(en)
|
2015-02-25 |
2023-08-22 |
The Regents Of The University Of California |
5ht agonists for treating disorders
|
CA2977521C
(en)
|
2015-02-27 |
2024-03-19 |
Curtana Pharmaceuticals, Inc. |
1-(aryl)-3-(heteroaryl) urea compounds and their use as olig2 inhibitors
|
CN107531687A
(zh)
|
2015-02-27 |
2018-01-02 |
加利福尼亚大学董事会 |
能够实现软骨复壮的小分子
|
HUE060104T2
(hu)
|
2015-02-27 |
2023-01-28 |
Verseon Int Corporation |
Szubsztituált pirazol vegyületek mint szerinproteázinhibitorok
|
CA2981504C
(en)
|
2015-03-30 |
2023-10-24 |
City Of Hope |
Mechanically interlocking complexes
|
CA2981530A1
(en)
|
2015-04-10 |
2016-10-13 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
EP3283462B1
(de)
|
2015-04-15 |
2020-12-02 |
Araxes Pharma LLC |
Kondensierte tricyclische inhibitoren von kras und anwendungsverfahren dafür
|
AU2016247858B2
(en)
|
2015-04-17 |
2020-10-15 |
Ludwig Institute For Cancer Research Ltd. |
PLK4 inhibitors
|
JP6704000B2
(ja)
|
2015-04-24 |
2020-06-03 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
Ror1−ror2結合のモジュレーター
|
CA2986030A1
(en)
|
2015-05-15 |
2016-11-24 |
City Of Hope |
Chimeric antigen receptor compositions
|
US10787664B2
(en)
|
2015-05-26 |
2020-09-29 |
City Of Hope |
Compounds of chemically modified oligonucleotides and methods of use thereof
|
MA42510A
(fr)
|
2015-06-10 |
2018-06-06 |
Biogen Ma Inc |
Formes et compositions d'inhibiteurs biaryles de la tyrosine kinase de bruton
|
WO2016201169A1
(en)
|
2015-06-10 |
2016-12-15 |
City Of Hope |
Compositions of and methods of treatment with zwitterionic polysaccharide
|
MA42242A
(fr)
|
2015-06-24 |
2018-05-02 |
Principia Biopharma Inc |
Inhibiteurs de la tyrosine kinase
|
WO2017004357A1
(en)
|
2015-07-02 |
2017-01-05 |
City Of Hope |
Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
EP3719016A1
(de)
|
2015-08-04 |
2020-10-07 |
Rigel Pharmaceuticals, Inc. |
Benzazolverbindungen und verfahren zur herstellung und verwendung der verbindungen
|
CN108135958B
(zh)
|
2015-08-06 |
2022-03-04 |
希望之城 |
细胞穿透蛋白-抗体缀合物及其使用方法
|
WO2017040693A1
(en)
|
2015-08-31 |
2017-03-09 |
The Regents Of The University Of California |
Broad spectrum antiviral compounds and uses thereof
|
WO2017040982A1
(en)
|
2015-09-02 |
2017-03-09 |
The Regents Of The University Of California |
Her3 ligands and uses thereof
|
CN108349900A
(zh)
|
2015-09-04 |
2018-07-31 |
希望之城 |
雄激素受体拮抗剂
|
US11253521B2
(en)
|
2015-09-25 |
2022-02-22 |
Ludwig Institute For Cancer Research Ltd |
3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators
|
US10689356B2
(en)
|
2015-09-28 |
2020-06-23 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
US10647703B2
(en)
|
2015-09-28 |
2020-05-12 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
US10858343B2
(en)
|
2015-09-28 |
2020-12-08 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2017058915A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
EP3356359B1
(de)
|
2015-09-28 |
2021-10-20 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
US10730867B2
(en)
|
2015-09-28 |
2020-08-04 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
US10875842B2
(en)
|
2015-09-28 |
2020-12-29 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
JP7038045B2
(ja)
|
2015-10-15 |
2022-03-17 |
シティ・オブ・ホープ |
ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにその使用方法
|
EP3364977A4
(de)
|
2015-10-19 |
2019-09-04 |
Araxes Pharma LLC |
Verfahren zum screening von inhibitoren von ras
|
US10662218B2
(en)
|
2015-10-23 |
2020-05-26 |
Erx Pharmaceuticals, Inc. |
Analogs of celastrol
|
KR20180101329A
(ko)
|
2015-10-23 |
2018-09-12 |
선에시스 파마슈티컬스 인코포레이티드 |
암 치료에 사용하기 위한 헤테로시클릭 pdk1 억제제
|
US11058700B2
(en)
|
2015-10-28 |
2021-07-13 |
City Of Hope |
Macrocyclic lactones and uses thereof as modulators of purinergic receptors
|
US10414757B2
(en)
|
2015-11-16 |
2019-09-17 |
Araxes Pharma Llc |
2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
|
US9988357B2
(en)
|
2015-12-09 |
2018-06-05 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
US20190119259A1
(en)
|
2015-12-10 |
2019-04-25 |
City Of Hope |
Cell penetrating cyanine-coupled antibodies
|
AU2016379444B2
(en)
|
2015-12-24 |
2021-04-29 |
The Regents Of The University Of California |
CFTR regulators and methods of use thereof
|
KR20180101416A
(ko)
|
2015-12-24 |
2018-09-12 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
Cftr 조절제 및 이의 이용 방법
|
AU2016380349B2
(en)
|
2015-12-30 |
2020-10-29 |
Nqp 1598, Ltd. |
Metalloenzyme inhibitor compounds
|
WO2017120198A1
(en)
|
2016-01-05 |
2017-07-13 |
The Regents Of The University Of California |
Benzothiazole amphiphiles
|
US10519442B2
(en)
|
2016-02-11 |
2019-12-31 |
City Of Hope |
Twist signaling inhibitor compositions and methods of using the same
|
EP3430017B1
(de)
|
2016-03-17 |
2023-01-25 |
The Regents of The University of California |
Zusammensetzungen und verfahren zur behandlung von parasitären krankheiten
|
US10822312B2
(en)
|
2016-03-30 |
2020-11-03 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
EP3458448B1
(de)
|
2016-04-25 |
2021-06-23 |
Forma Therapeutics, Inc. |
Fasn-hemmer zur behandlung der nicht-alkoholischen steatohepatitis
|
EP3448519A4
(de)
|
2016-04-29 |
2020-01-22 |
Board Of Regents, The University Of Texas System |
Sigma-rezeptor-bindemittel
|
TWI763668B
(zh)
|
2016-05-05 |
2022-05-11 |
美商嘉來克生命科學有限責任公司 |
整合應激途徑之調節劑
|
TW201808914A
(zh)
|
2016-05-05 |
2018-03-16 |
嘉來克生命科學有限責任公司 |
整合應激途徑之調節劑
|
UA121354C2
(uk)
|
2016-05-12 |
2020-05-12 |
Анакор Фармасутікалз, Інк. |
Нові сполуки для лікування паразитарних захворювань
|
US10918648B2
(en)
|
2016-05-26 |
2021-02-16 |
The Regents Of The University Of California |
Estrogen receptor modulator combinations
|
JP7065840B2
(ja)
|
2016-06-27 |
2022-05-12 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
2,4-ジアミノ-ピリミジン化合物ならびに該化合物の作製法および使用法
|
KR102515813B1
(ko)
|
2016-06-29 |
2023-03-30 |
프린시피아 바이오파마, 인코퍼레이티드 |
2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴의 변형 방출 제제
|
WO2018013609A2
(en)
|
2016-07-11 |
2018-01-18 |
The Regents The University Of California |
Synthetic melanin nanoparticles uses thereof
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
WO2018017153A1
(en)
|
2016-07-21 |
2018-01-25 |
Biogen Ma Inc. |
Succinate forms and compositions of bruton's tyrosine kinase inhibitors
|
US10179787B2
(en)
|
2016-07-29 |
2019-01-15 |
Flx Bio, Inc. |
Chemokine receptor modulators and uses thereof
|
US11542261B2
(en)
|
2016-08-17 |
2023-01-03 |
Children's Hospital Medical Center |
Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
|
US11254667B2
(en)
|
2016-08-17 |
2022-02-22 |
Children's Hospital Medical Center |
Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors
|
WO2018039612A1
(en)
|
2016-08-26 |
2018-03-01 |
The Regents Of The University Of California |
Compositions and methods for promoting hair growth with mpc1 inhibitors
|
JP7063885B2
(ja)
|
2016-09-13 |
2022-05-09 |
ザ ジャクソン ラボラトリー |
標的にされた増大するdna脱メチル化
|
CA3036852A1
(en)
|
2016-09-15 |
2018-03-22 |
City Of Hope |
Dithio etp derivatives
|
US10849955B2
(en)
|
2016-09-28 |
2020-12-01 |
City Of Hope |
Methods of treating pancreatic cancer using GPCR antagonists
|
EP3519402A1
(de)
|
2016-09-29 |
2019-08-07 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
US10377743B2
(en)
|
2016-10-07 |
2019-08-13 |
Araxes Pharma Llc |
Inhibitors of RAS and methods of use thereof
|
JP7170634B2
(ja)
|
2016-10-26 |
2022-11-14 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
Irak阻害剤としての使用のためのオキサゾール誘導体およびその調製のための方法
|
WO2018081294A1
(en)
|
2016-10-26 |
2018-05-03 |
Rigel Pharmaceuticals, Inc. |
Pyrazole amide compounds as irak inhibitors
|
US10646540B2
(en)
|
2016-11-18 |
2020-05-12 |
City Of Hope |
Peptide inhibitors of twist
|
JP7144411B2
(ja)
|
2016-11-30 |
2022-09-29 |
ネオンク テクノロジーズ インク. |
ペリリルアルコール-3-ブロモピルベート複合体及びがんの治療方法
|
JP7191828B2
(ja)
|
2016-12-15 |
2022-12-19 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
がん治療のための組成物および方法
|
WO2018125799A2
(en)
|
2016-12-29 |
2018-07-05 |
Viamet Pharmaceuticals (Bermuda), Ltd. |
Metalloenzyme inhibitor compounds
|
KR20190129034A
(ko)
|
2016-12-29 |
2019-11-19 |
세레니티 테라퓨틱스 (버뮤다), 리미티드 |
금속효소 억제제 화합물
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
US11358959B2
(en)
|
2017-01-26 |
2022-06-14 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
US11274093B2
(en)
|
2017-01-26 |
2022-03-15 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
CN110382482A
(zh)
|
2017-01-26 |
2019-10-25 |
亚瑞克西斯制药公司 |
稠合的杂-杂二环化合物及其使用方法
|
US11279689B2
(en)
|
2017-01-26 |
2022-03-22 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
|
JP2020521741A
(ja)
|
2017-05-25 |
2020-07-27 |
アラクセス ファーマ エルエルシー |
がんの処置のための化合物およびその使用の方法
|
CN110831933A
(zh)
|
2017-05-25 |
2020-02-21 |
亚瑞克西斯制药公司 |
喹唑啉衍生物作为突变kras、hras或nras的调节剂
|
CA3063440A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Covalent inhibitors of kras
|
WO2018237145A1
(en)
|
2017-06-21 |
2018-12-27 |
Mitokinin, Inc. |
COMPOSITIONS AND METHODS USING THEM FOR THE TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE
|
CA3068305A1
(en)
|
2017-06-29 |
2019-01-03 |
Rigel Pharmaceuticals, Inc. |
Kinase inhibitors and methods for making and using
|
WO2019006371A1
(en)
|
2017-06-30 |
2019-01-03 |
City Of Hope |
COMPOSITIONS AND METHODS FOR MODULATING MACROPHAGE ACTIVITY
|
US11389460B2
(en)
|
2017-09-15 |
2022-07-19 |
City Of Hope |
Methods and compositions for treating endometrial cancer
|
WO2019067015A1
(en)
|
2017-09-29 |
2019-04-04 |
City Of Hope |
RECEPTORS OF CHIMERIC ANTIGENS AND BISPECIFIC ANTIBODIES FOR THE TREATMENT OF COAT CELL LYMPHOMA
|
EP3688028A2
(de)
|
2017-09-29 |
2020-08-05 |
Genentech, Inc. |
Antibiotische peptidkomplexe und verfahren zu deren verwendung
|
US11260048B2
(en)
|
2017-10-03 |
2022-03-01 |
The Schepens Eye Research Institute, Inc. |
Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same
|
CA3078942A1
(en)
|
2017-10-10 |
2019-04-18 |
Syros Pharmaceuticals, Inc. |
Pyrrolotriazine compounds and methods of inhibiting tam kinases
|
US11618780B2
(en)
|
2017-10-20 |
2023-04-04 |
City Of Hope |
Composition and method for activating latent human immunodeficiency virus (HIV)
|
UY37956A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
AU2018358160B2
(en)
|
2017-11-02 |
2023-03-16 |
Abbvie Inc. |
Modulators of the integrated stress pathway
|
BR112020008817B8
(pt)
|
2017-11-02 |
2023-10-03 |
Abbvie Inc |
Compostos moduladores da via de estresse integrada
|
UY37957A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
BR112020008827A2
(pt)
|
2017-11-02 |
2020-10-20 |
Calico Life Sciences Llc |
moduladores da via de estresse integrada
|
UY37958A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
CA3080964A1
(en)
|
2017-11-02 |
2019-05-09 |
Calico Life Sciences Llc |
Modulators of the integrated stress pathway
|
JP2021501781A
(ja)
|
2017-11-02 |
2021-01-21 |
カリコ ライフ サイエンシーズ エルエルシー |
統合的ストレス経路の調節剤
|
AU2018360854B2
(en)
|
2017-11-02 |
2023-03-30 |
Abbvie Inc. |
Modulators of the integrated stress pathway
|
JP2021502345A
(ja)
|
2017-11-06 |
2021-01-28 |
ラプト・セラピューティクス・インコーポレイテッド |
抗がん剤
|
US20210292410A1
(en)
|
2017-12-07 |
2021-09-23 |
Morphosys Ag |
Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
|
JP7292299B2
(ja)
|
2017-12-07 |
2023-06-16 |
アンプリックス ファーマシューティカルズ,インク. |
複素環式の置換ピリジン誘導体である抗真菌薬
|
WO2019126037A1
(en)
|
2017-12-19 |
2019-06-27 |
City Of Hope |
Modified tracrrnas grnas, and uses thereof
|
AU2019209470A1
(en)
|
2018-01-16 |
2020-08-13 |
Syros Pharmaceuticals, Inc. |
Inhibitors of cyclin-dependent kinase 7 (CDK7)
|
AU2019209475A1
(en)
|
2018-01-16 |
2020-08-20 |
Syros Pharmaceuticals, Inc. |
Inhibitors of cyclin-dependent kinase 7 (CDK7)
|
RU2020128176A
(ru)
|
2018-01-26 |
2022-03-02 |
Рапт Терапьютикс, Инк. |
Модуляторы рецепторов хемокинов и их применение
|
WO2019157195A1
(en)
|
2018-02-08 |
2019-08-15 |
Neonc Technologies, Inc |
Methods of permeabilizing the blood brain barrier
|
EP3765459A1
(de)
|
2018-03-13 |
2021-01-20 |
Shire Human Genetic Therapies, Inc. |
Substituierte imidazopyridine als inhibitoren von plasmakallikrein und verwendungen davon
|
JP7427655B2
(ja)
|
2018-04-27 |
2024-02-05 |
スプルース バイオサイエンシーズ,インク. |
精巣副腎残存腫瘍および卵巣副腎残存腫瘍を処置するための方法
|
JP7381492B2
(ja)
|
2018-05-01 |
2023-11-15 |
レヴォリューション・メディスンズ,インコーポレイテッド |
Mtor阻害剤としてのc26-連結ラパマイシン類似体
|
WO2019212990A1
(en)
|
2018-05-01 |
2019-11-07 |
Revolution Medicines, Inc. |
C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors
|
EP3788044B1
(de)
|
2018-05-03 |
2023-08-09 |
Rigel Pharmaceuticals, Inc. |
Rip1-inhibitorverbindungen und verfahren zu ihrer herstellung und verwendung
|
EA202092581A1
(ru)
|
2018-05-03 |
2021-04-08 |
Ригел Фармасьютикалз, Инк. |
Соединения, ингибирующие rip1, а также способы их получения и применения
|
EP3787618A4
(de)
|
2018-05-04 |
2022-05-04 |
Cirius Therapeutics, Inc. |
Thiazolidindionanaloga zur behandlung von nafld und stoffwechselerkrankungen
|
JP2021527051A
(ja)
|
2018-06-05 |
2021-10-11 |
ラプト・セラピューティクス・インコーポレイテッド |
ピラゾロ−ピリミジン−アミノ−シクロアルキル化合物及びその治療的使用
|
SG11202012820PA
(en)
|
2018-06-21 |
2021-01-28 |
Calico Life Sciences Llc |
Protein tyrosine phosphatase inhibitors and methods of use thereof
|
CA3104653A1
(en)
|
2018-06-25 |
2020-01-02 |
Amplyx Pharmaceuticals, Inc. |
Pyridine derivatives substituted by heterocyclic ring and amino group
|
US20210221864A1
(en)
|
2018-08-24 |
2021-07-22 |
City Of Hope |
Masked cytokine conjugates
|
TWI771621B
(zh)
|
2018-10-11 |
2022-07-21 |
美商嘉來克生命科學有限責任公司 |
整合應激路徑之前藥調節劑
|
WO2020092845A1
(en)
|
2018-11-01 |
2020-05-07 |
Rigel Pharmaceuticals, Inc. |
Method and composition embodiments for treating acute myeloid leukemia
|
MX2021004517A
(es)
|
2018-11-01 |
2021-11-04 |
Lynk Pharmaceuticals Co Ltd |
Inhibidores de cinasa de janus 1 triciclicos y composiciones y metodos de los mismos.
|
CN114025844B
(zh)
|
2019-03-14 |
2022-07-26 |
卡里科生命科学有限责任公司 |
蛋白酪氨酸磷酸酶抑制剂及其使用方法
|
PE20220572A1
(es)
|
2019-04-30 |
2022-04-20 |
Calico Life Sciences Llc |
Moduladores de la via integrada del estres
|
EP3968979A4
(de)
|
2019-05-15 |
2023-03-01 |
Bexson Biomedical, Inc. |
Ketaminformulierung für subkutane injektion
|
US20200377518A1
(en)
|
2019-05-29 |
2020-12-03 |
Rigel Pharmaceuticals, Inc. |
Method of preventing and treating thrombosis
|
MX2022001596A
(es)
|
2019-08-08 |
2022-03-11 |
Rigel Pharmaceuticals Inc |
Compuestos y metodos para tratar sindrome de liberacion de citocinas.
|
MX2022001890A
(es)
|
2019-08-14 |
2022-04-26 |
Rigel Pharmaceuticals Inc |
Metodo para bloquear o mejorar el sindrome de liberacion de citocinas.
|
CA3152264A1
(en)
|
2019-08-30 |
2021-03-04 |
Rigel Pharmaceuticals, Inc. |
Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations
|
JOP20220056A1
(ar)
|
2019-09-06 |
2023-01-30 |
Rigel Pharmaceuticals Inc |
مركبات rip1 تثبيطية وطرق عملها واستخدامها
|
US11479543B2
(en)
|
2019-09-06 |
2022-10-25 |
Rigel Pharmaceuticals, Inc. |
Heterocyclic RIP1 kinase inhibitors
|
EP4031566A1
(de)
|
2019-09-18 |
2022-07-27 |
Novartis AG |
Nkg2d-fusionsproteine und verwendungen davon
|
WO2021055589A1
(en)
|
2019-09-18 |
2021-03-25 |
Shire Human Genetic Therapies, Inc. |
Heteroaryl plasma kallikrein inhibitors
|
CN114728962A
(zh)
|
2019-09-18 |
2022-07-08 |
武田药品工业有限公司 |
血浆激肽释放酶抑制剂及其用途
|
CN115298184A
(zh)
|
2019-11-07 |
2022-11-04 |
里格尔药品股份有限公司 |
杂环rip1抑制化合物
|
WO2021097339A1
(en)
|
2019-11-13 |
2021-05-20 |
Rapt Therapeutics, Inc. |
Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof
|
EP4077291A1
(de)
|
2019-12-18 |
2022-10-26 |
Calico Life Sciences LLC |
Protein-tyrosin-phosphatase-inhibitoren und verfahren zur verwendung davon
|
AU2021276656A1
(en)
|
2020-05-19 |
2022-11-24 |
Cybin Irl Limited |
Deuterated tryptamine derivatives and methods of use
|
KR20230053611A
(ko)
|
2020-08-18 |
2023-04-21 |
사이빈 아이알엘 리미티드 |
펜에틸아민 유도체, 조성물, 및 사용 방법
|
JP2023548605A
(ja)
|
2020-11-02 |
2023-11-17 |
トレセラ コーポレーション |
デオキシシチジンキナーゼ阻害剤の結晶形態およびその使用
|
JP2023551145A
(ja)
|
2020-11-18 |
2023-12-07 |
ベクソン バイオメディカル,インク. |
医薬化合物の錯化剤塩製剤
|
US20240058344A1
(en)
|
2020-12-18 |
2024-02-22 |
Cornell University |
Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
|
US20220288047A1
(en)
|
2021-03-03 |
2022-09-15 |
Rigel Pharmaceuticals, Inc. |
Method for treating a disease or condition using a pyrazole compound or formulation thereof
|
TW202300490A
(zh)
|
2021-03-11 |
2023-01-01 |
美商雷傑製藥公司 |
雜環rip1激酶抑制劑
|
US11918582B2
(en)
|
2021-03-15 |
2024-03-05 |
Rapt Therapeutics, Inc. |
Pyrazole pyrimidine compounds and uses thereof
|
EP4308228A1
(de)
|
2021-03-17 |
2024-01-24 |
Takeda Pharmaceutical Company Limited |
Plasmakallikreinhemmer
|
CN117355523A
(zh)
|
2021-03-17 |
2024-01-05 |
武田药品工业株式会社 |
血浆激肽释放酶的多环抑制剂
|
WO2022197763A1
(en)
|
2021-03-17 |
2022-09-22 |
Shire Human Genetic Therapies, Inc. |
Inhibitors of plasma kallikrein
|
EP4308230A1
(de)
|
2021-03-17 |
2024-01-24 |
Takeda Pharmaceutical Company Limited |
Heteroaryl-inhibitoren von plasmakallikrein
|
CN117396473A
(zh)
|
2021-03-17 |
2024-01-12 |
武田药品工业株式会社 |
血浆激肽释放酶的咪唑并吡啶基抑制剂
|
WO2023156450A1
(en)
|
2022-02-15 |
2023-08-24 |
Cybin Irl Limited |
Therapeutic phenethylamine compositions and methods of use
|
WO2023156453A1
(en)
|
2022-02-15 |
2023-08-24 |
Cybin Irl Limited |
Phenethylamine derivatives, compositions, and methods of use
|
WO2023183377A1
(en)
|
2022-03-23 |
2023-09-28 |
Rigel Pharmaceuticals, Inc. |
Pyrimid-2-yl-pyrazole compounds as irak inhibitors
|
US20230312568A1
(en)
|
2022-03-31 |
2023-10-05 |
Rigel Pharmaceuticals, Inc. |
Tricyclic irak inhibitors
|
US20230322741A1
(en)
|
2022-04-06 |
2023-10-12 |
Rapt Therapeutics, Inc. |
Chemokine receptor modulators and uses thereof
|
CN114504550B
(zh)
*
|
2022-04-18 |
2022-08-19 |
中山大学中山眼科中心 |
一种包含甲硝唑的眼用凝胶及其制备方法
|